Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration

The purpose of the study was to estimate the effectiveness of using ranibizumab in combination with medotilin drug in the treatment of neovascular age-related macular degeneration (AMD). Material and methods. 50 patients (65 eyes) aged 41 to 88 (ave. 68.5 ± 0.98 years) with neovascular AMD were foll...

Full description

Saved in:
Bibliographic Details
Main Authors: F. A. Bakhritdinova, A. F. Yusupov, Sh. A. Mukhanov
Format: Article
Language:Russian
Published: Real Time Ltd 2018-10-01
Series:Российский офтальмологический журнал
Subjects:
Online Access:https://roj.igb.ru/jour/article/view/69
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849696594574704640
author F. A. Bakhritdinova
A. F. Yusupov
Sh. A. Mukhanov
author_facet F. A. Bakhritdinova
A. F. Yusupov
Sh. A. Mukhanov
author_sort F. A. Bakhritdinova
collection DOAJ
description The purpose of the study was to estimate the effectiveness of using ranibizumab in combination with medotilin drug in the treatment of neovascular age-related macular degeneration (AMD). Material and methods. 50 patients (65 eyes) aged 41 to 88 (ave. 68.5 ± 0.98 years) with neovascular AMD were followed-up. All patients were assigned treatment consisting of three intravitreal ranibizumab injections with an interval of 1 month between injections. Of these, 25 patients (34 eyes) were additionally given 4 ml of medotilin intramuscularly once a day for 10 days. Results. Combined treatment with ranibizumab and medotilin showed a statistically significant improvement of functional parameters: visual acuity, light sensitivity and flicker ERG as compared to the control group. Conclusion. Medotilin, which has neuroprotective action, enhances the effect of angiogenesis inhibitors drugs in all forms of neovascular AMD and promotes statistically significant increase of the functional condition of the central retina area, which is confirmed by electroretinography data // Russian Ophthalmological Journal, 2017; 1: 9-14. doi: 10.21516/2072-0076-2017-10-1-9-14.
format Article
id doaj-art-86402188e28641ebb7903f90fd3dca03
institution DOAJ
issn 2072-0076
2587-5760
language Russian
publishDate 2018-10-01
publisher Real Time Ltd
record_format Article
series Российский офтальмологический журнал
spelling doaj-art-86402188e28641ebb7903f90fd3dca032025-08-20T03:19:24ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602018-10-0110191410.21516/2072-0076-2017-10-1-9-1469Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degenerationF. A. Bakhritdinova0A. F. Yusupov1Sh. A. Mukhanov2Tashkent Medical Academy, Ministry of Healthcare of the Republic of Uzbekistan, Tashkent, UzbekistanJoint Venture “SIHAT KO’Z” LLC, Tashkent, UzbekistanJoint Venture “SIHAT KO’Z” LLC, Tashkent, UzbekistanThe purpose of the study was to estimate the effectiveness of using ranibizumab in combination with medotilin drug in the treatment of neovascular age-related macular degeneration (AMD). Material and methods. 50 patients (65 eyes) aged 41 to 88 (ave. 68.5 ± 0.98 years) with neovascular AMD were followed-up. All patients were assigned treatment consisting of three intravitreal ranibizumab injections with an interval of 1 month between injections. Of these, 25 patients (34 eyes) were additionally given 4 ml of medotilin intramuscularly once a day for 10 days. Results. Combined treatment with ranibizumab and medotilin showed a statistically significant improvement of functional parameters: visual acuity, light sensitivity and flicker ERG as compared to the control group. Conclusion. Medotilin, which has neuroprotective action, enhances the effect of angiogenesis inhibitors drugs in all forms of neovascular AMD and promotes statistically significant increase of the functional condition of the central retina area, which is confirmed by electroretinography data // Russian Ophthalmological Journal, 2017; 1: 9-14. doi: 10.21516/2072-0076-2017-10-1-9-14.https://roj.igb.ru/jour/article/view/69возрастная макулярная дегенерацияхроническая неоваскуляризацияранибизумабмедотилинэлектроретинографияage-related macular degenerationchronic neovascularizationranibizumabmedotilinelectroretinography
spellingShingle F. A. Bakhritdinova
A. F. Yusupov
Sh. A. Mukhanov
Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
Российский офтальмологический журнал
возрастная макулярная дегенерация
хроническая неоваскуляризация
ранибизумаб
медотилин
электроретинография
age-related macular degeneration
chronic neovascularization
ranibizumab
medotilin
electroretinography
title Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
title_full Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
title_fullStr Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
title_full_unstemmed Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
title_short Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
title_sort optimizing the use of angiogenesis inhibitor in neovascular age related macular degeneration
topic возрастная макулярная дегенерация
хроническая неоваскуляризация
ранибизумаб
медотилин
электроретинография
age-related macular degeneration
chronic neovascularization
ranibizumab
medotilin
electroretinography
url https://roj.igb.ru/jour/article/view/69
work_keys_str_mv AT fabakhritdinova optimizingtheuseofangiogenesisinhibitorinneovascularagerelatedmaculardegeneration
AT afyusupov optimizingtheuseofangiogenesisinhibitorinneovascularagerelatedmaculardegeneration
AT shamukhanov optimizingtheuseofangiogenesisinhibitorinneovascularagerelatedmaculardegeneration